-
公开(公告)号：US12048793B2
公开(公告)日：2024-07-30
申请号：US17251552
申请日：2019-06-11
Applicant: EpicentRx, Inc.
Inventor： Bryan T. Oronsky , Scott Caroen , Tony R. Reid , Jeannie Williams
CPC classification number: A61M1/342 , A61M1/3673 , A61M1/38 , A61M2202/0216 , A61M2202/0275 , A61M2205/3337 , A61M2205/7545
Abstract: Devices, systems, and methods for medication infusion are described herein. In some embodiments, a system includes a patient access subassembly, a first fluid reservoir, a second fluid reservoir, and an assembly. The assembly can have a first configuration in which the patient access subassembly is in fluid communication with the first fluid reservoir via a first tube, a second configuration in which the first fluid reservoir is in fluid communication with the second fluid reservoir, and a third configuration in which the first fluid reservoir is in fluid communication with the patient access subassembly via a second tube, the first fluid reservoir fluidically isolated from the first tube in the third configuration.
-
22.发明授权公开(公告)号：US11999973B2
公开(公告)日：2024-06-04
申请号：US16604194
申请日：2018-04-10
Applicant: EpicentRx, Inc.
Inventor： Tony R. Reid , Bryan T. Oronsky , Christopher Larson
IPC: C12N7/00
CPC classification number: C12N7/00 , C12N2710/10321 , C12N2710/10322 , C12N2710/10332 , C12N2710/10352
Abstract: The invention relates to a method for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.
-
23.发明授权公开(公告)号：US11576895B2
公开(公告)日：2023-02-14
申请号：US16069012
申请日：2017-01-11
Applicant: EpicentRx, Inc.
Inventor： Bryan T. Oronsky , Jan Scicinski , Scott Caroen
IPC: A61K31/397 , A61P35/02 , A61P35/00 , A61K9/00 , A61K31/194 , A61K31/727 , A61K35/14 , A61K47/10 , A61K47/18 , A61K47/46 , A61K9/08
Abstract: The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.
-
公开(公告)号：US11160784B1
公开(公告)日：2021-11-02
申请号：US16456396
申请日：2019-06-28
Applicant: EpicentRx, Inc.
Inventor： Bryan T. Oronsky , Jan Scicinski
IPC: A61N5/10 , A61K31/397 , A61K31/495 , A61K9/00
Abstract: The invention provides therapeutic methods and kits for treating brain metastases using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and optionally an additional anti-cancer agent.
-
25.发明申请公开(公告)号：US20200157047A1
公开(公告)日：2020-05-21
申请号：US16341538
申请日：2017-10-13
Applicant: EpicentRx, Inc.
Inventor： Bryan T. Oronsky , Jan Scicinski
IPC: C07D205/04
Abstract: The invention provides sulfoxyalkyl organonitro and related compounds, compositions containing such compounds, and methods for using such compounds and compositions to treat medical disorders, such as a neurodegenerative disorder, autoimmune disease, infection, or cancer in a patient. Exemplary sulfoxyalkyl organonitro compounds described herein include ((2-(3,3-dinitroaze-tidin-1-yl)-2-oxoethyl)sulfinyl)-D-alanine and variants thereof.
-
Patent Agency Ranking
公开(公告)号：US20200078415A1
公开(公告)日：2020-03-12
申请号：US16604675
申请日：2018-04-12
Applicant: EpicentRx, Inc.
Inventor： Tony R. Reid , Christopher Larson , Bryan T. Oronsky
Abstract: The invention relates to a recombinant adenovirus comprising two or more therapeutic transgenes, e.g., two components of a heterodimeric cytokine, separated by a cleavable linker.
-
公开(公告)号：US10543208B2
公开(公告)日：2020-01-28
申请号：US15989862
申请日：2018-05-25
Applicant: EpicentRx, Inc.
Inventor： Bryan T. Oronsky , Jan Scicinski
IPC: A61K31/495 , A61K9/00 , A61K31/397 , A61K31/4745 , A61N5/10
Abstract: The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.
-
公开(公告)号：US20190125742A1
公开(公告)日：2019-05-02
申请号：US15989862
申请日：2018-05-25
Applicant: EpicentRx, Inc.
Inventor： Bryan T. Oronsky , Jan Scicinski
IPC: A61K31/495 , A61K9/00 , A61K31/397 , A61K31/4745
Abstract: The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.
-
公开(公告)号：US20160331771A1
公开(公告)日：2016-11-17
申请号：US15041813
申请日：2016-02-11
Applicant: EpicentRx, Inc.
Inventor： Bryan T. Oronsky , Peter Langecker
IPC: A61K31/7048 , A61K31/593 , A61K47/42 , A61K45/06 , A61K9/00
CPC classification number: A61K31/7048 , A61K9/0014 , A61K31/593 , A61K45/06 , A61K47/42 , A61K47/60 , A61K47/643 , A61K2300/00
Abstract: Provided are methods and compositions for treating and preventing hyperproliferative disorders such as psoriasis by administration of a cardiac glycoside alone or in combination locally or systemically with a calciotropic agents and/or a diffusion-limiting component, such a vasoconstrictor or collagen barrier.
Abstract translation: 本发明提供了通过单独施用强心苷或局部或全身组合使用光致剂和/或扩散限制成分如血管收缩剂或胶原屏障来治疗和预防过度增殖性疾病如牛皮癣的方法和组合物。
-
公开(公告)号：US11834492B2
公开(公告)日：2023-12-05
申请号：US16651079
申请日：2018-09-27
Applicant: EpicentRx, Inc.
Inventor： Christopher Larson , Tony R. Reid , Bryan T. Oronsky
IPC: C07K14/715 , A61P35/00 , C07K14/54 , C12N15/62 , A61K38/00
CPC classification number: C07K14/7155 , A61P35/00 , C07K14/5428 , C12N15/62 , A61K38/00 , C07K2319/03 , C07K2319/30 , C07K2319/50
Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.025 seconds)
